2-(4-morpholinoanilino)-6-cyclohexylaminopurine and ER-Negative PR-Negative HER2-Negative Breast Cancer

2-(4-morpholinoanilino)-6-cyclohexylaminopurine has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Jiang, M; Li, C; Li, J; Liang, D; Liu, J; Sun, W; Wang, S; Yang, X; Zhang, C; Zhang, M; Zhou, X	1

Reviews

1 review(s) available for 2-(4-morpholinoanilino)-6-cyclohexylaminopurine and ER-Negative PR-Negative HER2-Negative Breast Cancer

Article	Year
Molecular design and anticancer activities of small-molecule monopolar spindle 1 inhibitors: A Medicinal chemistry perspective. European journal of medicinal chemistry, 2019, Aug-01, Volume: 175 Topics: Antineoplastic Agents; Cell Cycle Proteins; Drug Design; Drug Resistance; Humans; M Phase Cell Cycle Checkpoints; Protein Conformation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Spindle Apparatus; Structure-Activity Relationship; Triple Negative Breast Neoplasms	2019

Article

Year

Molecular design and anticancer activities of small-molecule monopolar spindle 1 inhibitors: A Medicinal chemistry perspective.

European journal of medicinal chemistry, 2019, Aug-01, Volume: 175

Topics: Antineoplastic Agents; Cell Cycle Proteins; Drug Design; Drug Resistance; Humans; M Phase Cell Cycle Checkpoints; Protein Conformation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Spindle Apparatus; Structure-Activity Relationship; Triple Negative Breast Neoplasms

2019